Recent submissions

  • Cyclin A triggers Mitosis either via the Greatwall kinase pathway or Cyclin B. 

    Hégarat, N; Crncec, A; Suarez Peredo Rodriguez, MF; Echegaray Iturra, F; Gu, Y; Busby, O; Lang, PF; Barr, AR; Bakal, C; Kanemaki, MT; Lamond, AI; Novak, B; Ly, T; Hochegger, H
    Two mitotic cyclin types, cyclin A and B, exist in higher eukaryotes, but their specialised functions in mitosis are incompletely understood. Using degron tags for rapid inducible protein removal, we analyse how acute ...
  • Leveraging Genome and Phenome-Wide Association Studies to Investigate Genetic Risk of Acute Lymphoblastic Leukemia. 

    Semmes, EC; Vijayakrishnan, J; Zhang, C; Hurst, JH; Houlston, RS; Walsh, KM (2020-05-28)
    BACKGROUND:Genome-wide association studies (GWAS) of childhood cancers remain limited, highlighting the need for novel analytic strategies. We describe a hybrid GWAS and phenome-wide association study (PheWAS) approach to ...
  • A mouse SWATH-MS reference spectral library enables deconvolution of species-specific proteomic alterations in human tumour xenografts. 

    Krasny, L; Bland, P; Burns, J; Lima, NC; Harrison, PT; Pacini, L; Elms, ML; Ning, J; Garcia Martinez, V; Yu, Y-R; Acton, SE; Ho, P-C; Calvo, F; Swain, A; Howard, BA; Natrajan, RC; Huang, PH (2020-06-03)
    SWATH-mass spectrometry (MS) enables accurate and reproducible proteomic profiling in multiple model organisms including the mouse. Here we present a comprehensive mouse reference spectral library (MouseRefSWATH) that ...
  • DNA origami-based single-molecule force spectroscopy elucidates RNA Polymerase III pre-initiation complex stability. 

    Kramm, K; Schröder, T; Gouge, J; Vera, AM; Gupta, K; Heiss, FB; Liedl, T; Engel, C; Berger, I; Vannini, A; Tinnefeld, P; Grohmann, D (2020-06-05)
    The TATA-binding protein (TBP) and a transcription factor (TF) IIB-like factor are important constituents of all eukaryotic initiation complexes. The reason for the emergence and strict requirement of the additional ...
  • Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. 

    Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; Collett, C; Waterhouse, A; Jones, JR; Kishore, B; Garg, M; Williams, CD; Karunanithi, K; Lindsay, J; Allotey, D; Shafeek, S; Jenner, MW; Cook, G; Russell, NH; Kaiser, MF; Drayson, MT; Owen, RG; Gregory, WM; Morgan, GJ; UK NCRI Haematological Oncology Clinical Studies Group (2020-06-04)
    The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved. We addressed this question in a large phase III randomized trial, Myeloma XI. Patients ...
  • Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. 

    Cook, G; John Ashcroft, A; Pratt, G; Popat, R; Ramasamy, K; Kaiser, M; Jenner, M; Henshaw, S; Hall, R; Sive, J; Stern, S; Streetly, M; Bygrave, C; Soutar, R; Rabin, N; Jackson, GH; United Kingdom Myeloma Forum (2020-05-21)
  • MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma. 

    King, D; Li, XD; Almeida, GS; Kwok, C; Gravells, P; Harrison, D; Burke, S; Hallsworth, A; Jamin, Y; George, S; Robinson, SP; Lord, CJ; Poon, E; Yeomanson, D; Chesler, L; Bryant, HE (2020-06-09)
    This study investigates the influence expression of the MYCN oncogene has on the DNA damage response, replication fork progression and sensitivity to PARP inhibition in neuroblastoma. In a panel of neuroblastoma cell lines, ...
  • Hybrid Gene Origination Creates Human-Virus Chimeric Proteins during Infection. 

    Ho, JSY; Angel, M; Ma, Y; Sloan, E; Wang, G; Martinez-Romero, C; Alenquer, M; Roudko, V; Chung, L; Zheng, S; Chang, M; Fstkchyan, Y; Clohisey, S; Dinan, AM; Gibbs, J; Gifford, R; Shen, R; Gu, Q; Irigoyen, N; Campisi, L; Huang, C; Zhao, N; Jones, JD; van Knippenberg, I; Zhu, Z; Moshkina, N; Meyer, L; Noel, J; Peralta, Z; Rezelj, V; Kaake, R; Rosenberg, B; Wang, B; Wei, J; Paessler, S; Wise, HM; Johnson, J; Vannini, A; Amorim, MJ; Baillie, JK; Miraldi, ER; Benner, C; Brierley, I; Digard, P; Łuksza, M; Firth, AE; Krogan, N; Greenbaum, BD; MacLeod, MK; van Bakel, H; Garcìa-Sastre, A; Yewdell, JW; Hutchinson, E; Marazzi, I (2020-06-17)
    RNA viruses are a major human health threat. The life cycles of many highly pathogenic RNA viruses like influenza A virus (IAV) and Lassa virus depends on host mRNA, because viral polymerases cleave 5'-m7G-capped host ...
  • Characterization of small PRESAGE (R) samples for measurements near the dosimeter edges 

    Costa, F; Doran, S; Adamovics, J; Nill, S; Hanson, IM; Oelfke, U; IOP (2019)
  • Tropomyosin receptor kinase inhibitors in the management of sarcomas. 

    Wilding, CP; Loong, HH; Huang, PH; Jones, RL (2020-07)
    PURPOSE OF REVIEW:Genetic aberrations resulting in tropomyosin receptor kinase (TRK) fusion proteins can drive oncogenesis and are postulated to occur in up to 1% of solid tumours. However, TRK fusions in adult sarcomas ...
  • Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. 

    Yap, TA; O'Carrigan, B; Penney, MS; Lim, JS; Brown, JS; de Miguel Luken, MJ; Tunariu, N; Perez-Lopez, R; Rodrigues, DN; Riisnaes, R; Figueiredo, I; Carreira, S; Hare, B; McDermott, K; Khalique, S; Williamson, CT; Natrajan, R; Pettitt, SJ; Lord, CJ; Banerji, U; Pollard, J; Lopez, J; de Bono, JS (2020-06-22)
    PURPOSE:Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging ...
  • A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic. 

    Tiu, C; Shinde, R; Yap, C; Rao Baikady, B; Banerji, U; Minchom, AR; de Bono, JS; Lopez, JS (2020-07)
  • Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE). 

    Talhouk, A; George, J; Wang, C; Budden, T; Tan, TZ; Chiu, DS; Kommoss, S; Leong, HS; Chen, S; Intermaggio, MP; Gilks, B; Nazeran, TM; Volchek, M; Elatre, W; Bentley, RC; Senz, J; Lum, A; Chow, V; Sudderuddin, H; Mackenzie, R; Leung, S; Liu, G; Johnson, D; Chen, B; Ovarian Cancer Study, A; Alsop, J; Banerjee, S; Behrens, S; Bodelon, C; Brand, AH; Brinton, LA; Carney, ME; Chiew, Y-E; Cushing-Haugen, KL; Cybulski, C; Ennis, D; Fereday, S; Fortner, RT; García-Donás, J; Gentry-Maharaj, A; Glasspool, R; Goranova, T; Greene, CS; Haluska, P; Harris, HR; Hendley, J; Hernandez, BY; Herpel, E; Jimenez-Linan, M; Karpinskyj, C; Kaufmann, SH; Keeney, G; Kennedy, CJ; Köbel, M; Koziak, J; Larson, MC; Lester, J; Lewsley, L-A; Lissowska, J; Lubiński, J; Luk, H; Macintyre, G; Mahner, S; McNeish, IA; Menkiszak, J; Nevins, N; Osorio, A; Oszurek, O; Palacios, J; Hinsley, S; Pearce, CL; Pike, MC; Piskorz, A; Ray-Coquard, I; Rhenius, V; Rodríguez-Antona, C; Sharma, R; Sherman, ME; Silva, D; Singh, N; Sinn, H-P; Slamon, DJ; Song, H; Steed, H; Stronach, EA; Thompson, PJ; Tołoczko-Grabarek, A; Trabert, B; Traficante, N; Tseng, C-C; Widschwendter, M; Wilkens, LR; Winham, SJ; Winterhoff, BJ; Beeghly-Fadiel, A; Benitez, J; Berchuck, A; Brenton, JD; Brown, R; Chang-Claude, J; Chenevix-Trench, G; DeFazio, A; Fasching, PA; Garcia, MJ; Gayther, SA; Goodman, MT; Gronwald, J; Henderson, MJ; Karlan, BY; Kelemen, LE; Menon, U; Orsulic, S; Pharoah, PDP; Wentzensen, N; Wu, AH; Shildkraut, J; Rossing, MA; Konecny, GE; Huntsman, DG; Huang, RY-J; Goode, EL; Ramus, SJ; Doherty, JA; Bowtell, DDL; Anglesio, MS (2020-06-17)
    PURPOSE:Gene-expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation ...
  • Patterns of practice for adaptive and real-time radiation therapy (POP-ART RT) part II: offline and online plan adaption for interfractional changes. 

    Bertholet, J; Anastasi, G; Noble, D; Bel, A; van Leeuwen, R; Roggen, T; Duchateau, M; Pilskog, S; Garibaldi, C; Tilly, N; García-Mollá, R; Bonaque, J; Oelfke, U; Aznar, MC; Heijmen, B (2020-06-21)
    The POP-ART RT study aims to determine to what extent and how intrafractional real-time respiratory motion management (RRMM), and plan adaptation for interfractional anatomical changes (ART) are used in clinical practice ...
  • UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants. 

    Hanson, H; Brady, AF; Crawford, G; Eeles, RA; Gibson, S; Jorgensen, M; Izatt, L; Sohaib, A; Tischkowitz, M; Evans, DG; Consensus Group Members (2020-06-22)
    Constitutional pathogenic variants in TP53 are associated with Li-Fraumeni syndrome or the more recently described heritable TP53-related cancer syndrome and are associated with increased lifetime risks of a wide spectrum ...
  • A genetic risk score to personalize prostate cancer screening, applied to population data. 

    Huynh-Le, M-P; Fan, CC; Karunamuni, R; Walsh, EI; Turner, EL; Lane, JA; Martin, RM; Neal, DE; Donovan, JL; Hamdy, FC; Parsons, JKK; Eeles, RA; Easton, DF; Kote-Jarai, Z; Amin Al Olama, A; Benlloch Garcia, S; Muir, K; Grönberg, H; Wiklund, F; Aly, M; Schleutker, J; Sipeky, C; Tammela, T; Nordestgaard, BG; Key, TJ; Travis, RC; Pharoah, PDP; Pashayan, N; Khaw, K-T; Thibodeau, SN; McDonnell, SK; Schaid, DJ; Maier, C; Vogel, W; Luedeke, M; Herkommer, K; Kibel, AS; Cybulski, C; Wokolorczyk, D; Kluzniak, W; Cannon-Albright, LA; Brenner, H; Schöttker, B; Holleczek, B; Park, JY; Sellers, TA; Lin, H-Y; Slavov, CK; Kaneva, RP; Mitev, VI; Batra, J; Clements, JA; Spurdle, AB; Teixeira, MR; Paulo, P; Maia, S; Pandha, H; Michael, A; Mills, IG; Andreassen, OA; Dale, AM; Seibert, TM (2020-06-24)
    BACKGROUND:A polygenic hazard score (PHS)-the weighted sum of 54 SNP genotypes-was previously validated for association with clinically significant prostate cancer and for improved prostate cancer screening accuracy. Here, ...
  • ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor positive breast cancer: A combined analysis of the phase III SoFEA and EFECT trials. 

    Turner, NC; Swift, C; Kilburn, LS; Fribbens, C; Beaney, M; Garcia-Murillas, I; Buzdar, AU; Roberston, JF; Gradishar, W; Piccart, M; Schiavon, G; Bliss, JM; Dowsett, M; Johnston, SRD; Chia, SK (2020-06-16)
    PURPOSE:ESR1 mutations are acquired frequently in hormone receptor positive (HR+) metastatic breast cancer after prior aromatase inhibitors (AI). We assessed the clinical utility of baseline ESR1 circulating tumor DNA ...
  • Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac. 

    Dunlop, A; Mitchell, A; Tree, A; Barnes, H; Bower, L; Chick, J; Goodwin, E; Herbert, T; Lawes, R; McNair, H; McQuaid, D; Mohajer, J; Nilawar, R; Pathmanathan, A; Smith, G; Hanson, I; Nill, S; Oelfke, U (2020-07)
    Introduction:MR-guided adapted radiotherapy (MRgART) using a high field MR-linac has recently become available. We report the estimated delivered fractional dose of the first five prostate cancer patients treated at our ...
  • Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids. 

    Koundouros, N; Karali, E; Tripp, A; Valle, A; Inglese, P; Perry, NJS; Magee, DJ; Anjomani Virmouni, S; Elder, GA; Tyson, AL; Dória, ML; van Weverwijk, A; Soares, RF; Isacke, CM; Nicholson, JK; Glen, RC; Takats, Z; Poulogiannis, G (2020-06-18)
    Oncogenic transformation is associated with profound changes in cellular metabolism, but whether tracking these can improve disease stratification or influence therapy decision-making is largely unknown. Using the iKnife ...
  • Prognostic Value of EndoPredict in Women with Hormone Receptor Positive, HER2-Negative Invasive Lobular Breast Cancer. 

    Sestak, I; Filipits, M; Buus, R; Rudas, M; Balic, M; Knauer, M; Kronenwett, R; Fitzal, F; Cuzick, J; Gnant, M; Greil, R; Dowsett, M; Dubsky, P (2020-06-19)
    PURPOSE:Invasive lobular carcinoma (ILC) accounts for approximately 5-15% of all invasive breast cancer cases. Most of the correlations between multigene assays and patient outcome were derived from studies based on patients ...

View more